Kiyatec develops functional precision oncology tests that measure live cancer cell responses to inform treatment selection. Its core product, the analytically validated 3D-Predict™ Glioma test, is commercially available in the United States and intended to inform therapy selection for glioblastoma and other high‑grade gliomas. The company published prospective clinical data in May 2021 showing the test can accurately predict individual patient responses to drugs, and identified responders who lived six months longer than non-responders on standard-of-care therapy. Kiyatec presented expanded clinical evidence at ASCO and SNO in 2022. Beyond clinical testing, Kiyatec operates a CLIA-certified lab, offers Drug Development Services to biopharma partners, and is developing assays for ovarian, breast, non-small cell lung cancers, and rare tumors. The new funding from patient‑focused venture philanthropy is aimed at supporting further commercialization and adoption of 3D-Predict™. Kiyatec’s core product is a clinically validated functional precision oncology platform that measures live tumor-cell responses to cancer drugs, including the commercially available 3D‑Predict™ Glioma test. The 3D‑Predict™ Glioma assay delivers a clinically attractive 7–10 day turnaround and has peer‑reviewed data (May 2021) showing statistically significant prediction of individual patient responses and a survival benefit in high‑grade glioma. Kiyatec also offers preclinical 3D cell‑culture services to biopharma clients to provide clinically relevant assessment of primary human drug response prior to clinical studies. The company operates a CLIA‑certified lab and is developing assays for ovarian, breast, non‑small cell lung cancers and rare tumors; 3D‑Predict™ Glioma is not commercially available in CA, NY or RI. Kiyatec reports growing revenue in its preclinical services business and has recently expanded laboratory and office space as the anchor tenant of Main Street Labs in Greenville, SC. Strategic partnerships, such as the announced collaboration with NICO Corporation to improve tissue quality, support broader adoption and platform performance. KIYATEC's core product is the 3D-Predict platform and associated tests that use proprietary ex vivo 3D cell culture systems to predict response to approved and investigational cancer drugs across solid tumors. The company operates a Clinical Services business that is validating clinical assays and conducting investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors in a CLIA-certified laboratory. Its Drug Development Services business partners with biopharmaceutical companies to characterize response dynamics for investigational drug candidates. KIYATEC released initial 3D-PREDICT clinical study data in late 2020 and published March 2021 results demonstrating platform expansion into immuno-oncology; the platform has been shown clinically predictive and analytically validated in ovarian cancer and high-grade gliomas. The company recently secured a $2.5 million investment from Seae Ventures to support implementation of its strategy to impact patients and providers. The Seae investment and board addition are positioned to provide healthcare industry relationships and support commercialization and strategic growth. KIYATEC leverages a proprietary ex vivo 3D cell culture platform to create patient-derived microtumors, or tumor spheroids, that are treated outside the body to potentially inform pre-treatment therapeutic decision-making. The company operates Drug Development Services that partner with biopharmaceutical firms to study response dynamics across solid tumors and a Clinical Services business validating clinical assays in a CLIA-certified laboratory. KIYATEC is currently enrolling patients in its pivotal 3D-PREDICT clinical study (NCT03561207) focused on validating assays that predict pre-treatment response for ovarian cancer and glioblastoma. The company is also engaged in investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors. KIYATEC has a longstanding research collaboration with the National Cancer Institute and participated in the NCI Investor Initiatives program. Management says validated assays could transform therapeutic selection and patient outcomes for the cancer types under study. KIYATEC offers cell-based drug-response profiling services built on a unique three-dimensional cell culture technology platform. The company generates data and develops assays to evaluate drug candidates prior to clinical trials. KIYATEC is pursuing a future clinical market to help oncologists select personalized therapies by testing live tumor-derived tissues for drug response. The aim of that clinical offering is to improve patient outcomes through more clinically relevant decision support. KIYATEC operates out of Greenville, S.C., at the Greenville Health Systems Institute for Translational Oncology Research. The company’s current focus is accelerating its pre-clinical services business while further developing its planned clinical services.

Total raised

$23M

Funding rounds

8

Latest round

Series C

Latest activity

Dec 2022